78: Pain

Published on 24/05/2015 by admin

Filed under Psychiatry

Last modified 22/04/2025

Print this page

rate 1 star rate 2 star rate 3 star rate 4 star rate 5 star
Your rating: none, Average: 2.9 (28 votes)

This article have been viewed 6274 times

CHAPTER 78 Pain

OVERVIEW

Pain, as determined by the International Association for the Study of Pain (IASP), is “an unpleasant sensory and emotional experience associated with actual or potential tissue damage or described in terms of such damage.”1 This chapter will describe the physiological aspects of pain transmission, pain terminology, and pain assessment; discuss the major classes of medications used to relieve pain; and outline the diagnosis and treatment of psychiatric conditions that often affect patients with chronic pain.

EPIDEMIOLOGY

Psychiatric co-morbidity (e.g., anxiety, depression, personality disorders, and substance use disorders [SUDs]) afflicts those with both non–cancer-related and cancer-related pain. Epidemiological studies indicate that roughly 30% of those in the general population with chronic musculoskeletal pain also have depression or an anxiety disorder.2 Similar rates exist in those with cancer pain. In clinic populations, 50% to 80% of pain patients have co-morbid psychopathology, including problematic personality traits. The personality (i.e., the characterological or temperamental) component of negative affect has been termed neuroticism, which may be best described as “a general personality maladjustment in which patients experience anger, disgust, sadness, anxiety, and a variety of other negative emotions.”3 Frequently, in pain clinics, maladaptive expressions of depression, anxiety, and anger are grouped together as disorders of negative affect, which have an adverse impact on the response to pain.4

Rates of substance dependence in chronic pain patients are also elevated relative to the general population, and several studies have found that 15% to 26% of chronic pain patients have a co-morbid substance (e.g., illegal drugs or prescription medications) dependence disorder.5 Prescription opiate addiction is a growing problem that affects approximately 5% of those who have been prescribed opiates for chronic pain (although good epidemiology studies are lacking). Other chapters in this textbook focus more specifically on SUDs. This chapter will concentrate on those with affective disorders and somatoform disorders in the setting of chronic pain.

While many chronic pain patients somatize and have difficulty adapting to it, a Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV-TR) diagnosis of somatization disorder per se, is less frequently encountered by those who treat patients with chronic pain. The DSM-IV-TR accounts for this distinction by classifying the somatoform component of a pain disorder into several categories (such as pain disorder associated with psychological factors, pain disorder associated with psychological factors and a general medical condition, and somatization disorder).

PATHOPHYSIOLOGY OF PAIN TRANSMISSION

Detection of noxious stimuli (i.e., nociception) starts with the activation of peripheral nociceptors (resulting in somatic pain) or with the activation of nociceptors in bodily organs (leading to visceral pain).

Tissue injury stimulates the nociceptors by the liberation of adenosine triphosphate (ATP), protons, kinins, and arachidonic acid from the injured cells; histamine, serotonin, prostaglandins, and bradykinin from the mast cells; and cytokines and nerve growth factor from the macrophages. These substances and decreased pH cause a decrease in the threshold for activation of the nociceptors, a process called peripheral sensitization. Subsequently, axons transmit the pain signal to the spinal cord, and to cell bodies in the dorsal root ganglia (Figure 78-1). Three different types of axons are involved in the transmission of pain from the skin to the dorsal horn. A-β fibers are the largest and most heavily myelinated fibers that transmit awareness of light touch. A-Δ fibers and C fibers are the primary nociceptive afferents. A-Δ fibers are 2 to 5 mcm in diameter and are thinly myelinated. They conduct “first pain,” which is immediate, rapid, and sharp, with a velocity of 20 m/sec. C fibers are 0.2 to 1.5 mcm in diameter and are unmyelinated. They conduct “second pain,” which is prolonged, burning, and unpleasant, at a speed of 0.5 m/sec.

image

Figure 78-1 Schematic diagram of neurological pathways for pain perception.

(From Hyman SH, Cassem NH: Pain. In Rubenstein E, Fedeman DD, editors: Scientific American medicine: current topics in medicine, subsection II, New York, 1989, Scientific American. Originally from Stern TA, Herman JB, editors: Psychiatry update and board preparation, 2004, McGraw-Hill.)

A-Δ and C fibers enter the dorsal root and ascend or descend one to three segments before synapsing with neurons in the lateral spinothalamic tract (in the substantia gelatinosa in the gray matter) (see Figure 78-1). Second pain transmitted with C-fibers is integrally related to chronic pain states. Repetitive C-fiber stimulation can result in a progressive increase of electrical discharges from second-order neurons in the spinal cord. NMDA receptors play a role when prolonged activation occurs. This pain amplification is related to a temporal summation of second pain or “wind-up.” This hyperexcitability of neurons in the dorsal horn contributes to central sensitization, which can occur as an immediate or as a delayed phenomenon. In addition to wind-up, central sensitization involves several factors: activation of A-beta fibers and lowered firing thresholds for spinal cord cells that modulate pain (i.e., they trigger pain more easily); neuroplasticity (a result of functional changes, including recruitment of a wide range of cells in the spinal cord so that touch or movement causes pain); convergence of cutaneous, vascular, muscle, and joint inputs (where one tissue refers pain to another); or aberrant connections (electrical short-circuits between the sympathetic and sensory nerves that produce causalgia). Inhibition of nociception in the dorsal horn is functionally quite important. Stimulation of the A-Δ fibers not only excites some neurons, but it also inhibits others. This inhibition of nociception through A-Δ fiber stimulation may explain the effects of acupuncture and transcutaneous electrical nerve stimulation (TENS).

The lateral spinothalamic tract crosses the midline and ascends toward the thalamus. At the level of the brainstem more than half of this tract synapses in the reticular activating system (in an area called the spinoreticular tract), in the limbic system, and in other brainstem regions (including centers of the autonomic nervous system). Another site of projections at this level is the periaqueductal gray (PAG) (Figure 78-2), which plays an important role in the brain’s system of endogenous analgesia. After synapsing in the thalamic nuclei, pain fibers project to the somatosensory cortex, located posterior to the Sylvian fissure in the parietal lobe, in Brodmann’s areas 1, 2, and 3. Endogenous analgesic systems involve endogenous peptides with opioid-like activity in the central nervous system (CNS) (e.g., endorphins, enkephalins, and dynorphins). Different opioid receptors (mu, kappa, and delta receptors) are involved in different effects of opiates. The centers involved in endogenous analgesia include the PAG, the anterior cingulate cortex (ACC), the amygdala, the parabrachial plexus (in the pons), and the rostral ventromedial medulla.

The descending analgesic pain pathway starts in the PAG (which is rich in endogenous opiates), projects to the rostral ventral medulla, and from there descends through the dorsolateral funiculus of the spinal cord to the dorsal horn. The neurons in the rostral ventral medulla use serotonin to activate endogenous analgesics (enkephalins) in the dorsal horn. This effect inhibits nociception at the level of the dorsal horn since neurons that contain enkephalins synapse with spinothalamic neurons. Additionally, there are noradrenergic neurons that project from the locus coeruleus (the main noradrenergic center in the CNS) to the dorsal horn and inhibit the response of dorsal horn neurons to nociceptive stimuli. The analgesic effect of tricyclic antidepressants (TCAs) and the serotonin-norepinephrine reuptake inhibitors (SNRIs) is thought to be related to an increase in serotonin and norepinephrine that inhibits nociception at the level of the dorsal horn, through their effects on enhancing descending pain inhibition from above.

CORTICAL SUBSTRATES FOR PAIN AND AFFECT

Advances in neuroimaging have linked the function of multiple areas in the brain with pain and affect. These areas (e.g., the ACC, the insula, and the dorsolateral prefrontal cortex [DLPFC]) form functional units through which psychiatric co-morbidity may amplify pain and disability (see Figure 78-2). These areas are part of the spinolimbic (also known as the medial) pain pathway,6 which runs parallel to the spinothalamic tract and receives direct input from the dorsal horn of the spinal cord. The interactions among the function of these areas, pain perception, and psychiatric illness are still being investigated. The spinolimbic pathway is involved in descending pain inhibition (which includes cortical and subcortical structures), whose function may be negatively affected by the presence of psychopathology. This, in turn, could lead to heightened pain perception. Coghill and colleagues7 have shown that differences in pain sensitivity between patients can be correlated with differences in activation patterns in the ACC, the insula, and the DLPFC. The anticipation of pain is also modulated by these areas, suggesting a mechanism by which anxiety about pain can amplify pain perception. The disruption or alteration of descending pain inhibition is a mechanism of neuropathic pain, which can be described as central sensitization that occurs at the level of the brain, a concept supported by recent neuroimaging studies of pain processing in the brains of patients with fibromyalgia.8 The ACC, the insula, and the DLPFC are also laden with opioid receptors, which are less responsive to endogenous opioids in pain-free subjects with high negative affect.9 Thus, negative affect may diminish the effectiveness of endogenous and exogenous opioids through direct effects on supraspinal opioid binding.

INTERACTIONS BETWEEN PAIN AND PSYCHOPATHOLOGY

The majority of patients with chronic pain and a psychiatric condition have an organic or physical basis for their pain. However, the perception of pain is amplified by co-morbid psychiatric disorders, which predispose patients to develop a chronic pain syndrome. This is commonly referred to as the diathesis-stress model, in which the combination of physical, social, and psychological stresses associated with a pain syndrome induces significant psychiatric co-morbidity.4 This can occur in patients with or without a pre-existing vulnerability to psychiatric illness (e.g., a genetic or temperamental risk factor). Regardless of the order of onset of psychopathology, patients with chronic pain and psychopathology report greater pain intensity, more pain-related disability, and a larger affective component to their pain than those without psychopathology. As a whole, studies indicate that it is not the specific qualities or symptomatology of depression, anxiety, or neuroticism, but the overall levels of psychiatric symptoms that are predictive of poor outcome.10 Depression, anxiety, and neuroticism are the psychiatric conditions that most often co-occur in patients with chronic pain, and those with a combination of pathologies are predisposed to the worst outcomes.

PAIN TERMINOLOGY

Acute pain is usually related to an identifiable injury or to a disease; it is self-limited, and resolves over hours to days or in a time frame that is associated with injury and healing. Acute pain is usually associated with objective autonomic features (e.g., tachycardia, hypertension, diaphoresis, mydriasis, or pallor).

Chronic pain (i.e., pain that persists beyond the normal time of healing or lasts longer than 6 months) involves different mechanisms in local, spinal, and supraspinal levels. Characteristic features include vague descriptions of pain and an inability to describe the pain’s timing and localization. It is usually helpful to determine the presence of a dermatomal pattern (Figure 78-3), to determine the presence of neuropathic pain, and to assess pain behavior.

image

Figure 78-3 Schematic diagram of segmental neuronal innervation by dermatomes.

(From Hyman SH, Cassem NH: Pain. In Rubenstein E, Fedeman DD, editors: Scientific American medicine: current topics in medicine, subsection II, New York, 1989, Scientific American. Originally from Stern TA, Herman JB, editors: Psychiatry update and board preparation, 2004, McGraw-Hill.)

Neuropathic pain is a disorder of neuromodulation. It is caused by an injured or dysfunctional central or peripheral nervous system; it is manifest by spontaneous, sharp, shooting, or burning pain, which may be distributed along dermatomes. Deafferentation pain, phantom limb pain, complex regional pain syndrome, diabetic neuropathy, central pain syndrome, trigeminal neuralgia, and postherpetic neuralgia are examples of neuropathic pain. Qualities of neuropathic pain include hyperalgesia (an increased response to stimuli that are normally painful); hyperesthesia (an exaggerated pain response to noxious stimuli [e.g., pressure or heat]); allodynia (pain with a stimulus not normally painful [e.g., light touch or cool air]); and hyperpathia (pain from a painful stimulus with a delay and a persistence that is distributed beyond the area of stimulation). Both acute and chronic pain conditions can involve neuropathic processes in addition to nociceptive causes of pain.

Idiopathic pain, previously referred to as psychogenic pain, is poorly understood. The presence of pain does not imply or exclude a psychological component. Typically, there is no evidence of an associated organic etiology or an anatomical pattern consistent with symptoms. Symptoms are often grossly out of proportion to an identifiable organic pathology.

Myofascial pain can arise from one or several of the following problems: hypertonic muscles, myofascial trigger points, arthralgias, and fatigue with muscle weakness. Myofascial pain is generally used to describe pain from muscles and connective tissue. Myofascial pain results from a primary diagnosis (e.g., fibromyalgia) or, as more often is the case, a co-morbid diagnosis (e.g., with vascular headache or with a psychiatric diagnosis).

ASSESSMENT OF PAIN

The evaluation of pain focuses first on five questions: (1) Is the pain intractable because of nociceptive stimuli (e.g., from the skin, bones, muscles, or blood vessels)? (2) Is the pain maintained by non-nociceptive mechanisms (i.e., have the spinal cord, brainstem, limbic system, and cortex been recruited as reverberating pain circuits)? (3) Is the complaint of pain primary (as occurs in disorders such as major depression or delusional disorder)? (4) Is there a more efficacious pharmacological treatment? (5) Have pain behavior and disability become more important than the pain itself? Answering these questions allows the mechanism(s) of the pain and suffering to be pursued. A psychiatrist’s physical examination of the pain patient typically includes examination of the painful area, muscles, and response to pinprick and light touch (Table 78-1).

Table 78-1 General Physical Examination of Pain by the Psychiatrist

Physical Finding Purpose of Examination
Motor deficits

Trigger points in head, neck, shoulder, and back muscles Evanescent, changeable pain, weakness, and numbness Does the psychological complaint preempt the physical? Abnormal sensory findings Sympathetic or vascular dysfunction Is there swelling, skin discoloration, or changes in sweating or temperature that suggest a vascular or sympathetic element to the pain? Uncooperativeness, erratic responses to the physical examination Is there an interpersonal aspect to the pain, causing abnormal pain behavior, as in somatoform disease?

The experience of pain is always subjective. However, several sensitive and reliable clinical instruments for the measurement of pain are available. These include the following:

CORE PSYCHOPATHOLOGY AND PAIN-RELATED PSYCHOLOGICAL SYMPTOMS

In patients with chronic pain, heightened emotional distress, negative affect, and elevated pain-related psychological symptoms (i.e., those that are a direct result of chronic pain, and when the pain is eliminated, the symptoms disappear) can all be considered as forms of psychopathology and psychiatric co-morbidity, since they represent impairments in mental health and involve maladaptive psychological responses to medical illness (Figure 78-4). This approach melds methods of classification from psychiatry and behavioral medicine to describe the scope of psychiatric disturbances in patients with chronic pain. In pain patients the most common manifestations of psychiatric co-morbidity involve one or more core psychopathologies in combination with pain-related psychological symptoms. Unfortunately, not all patients and their symptoms fit neatly into DSM categories of illness.

Pain-related anxiety (which includes state and trait anxiety related to pain) is the form of anxiety most germane to pain.11 Elevated levels of pain-related anxiety (such as fear of pain) also meet DSM-IV criteria for an anxiety disorder due to a general medical condition. Since anxiety straddles both domains of core psychopathology and pain-related psychological symptoms, the assessment of anxiety in a patient with chronic pain (as detailed below) must include a review of manifestations of generalized anxiety as well as pain-specific anxiety symptoms (e.g., physiological changes associated with the anticipation of pain).

Poor coping skills (often involving passive responses to chronic pain [e.g., remaining bed-bound] and mistakenly assuming that chronic pan is indicative of ongoing tissue damage), catastrophization (with cognitive distortions that are centered around pain), and low self-efficacy (i.e., with a low estimate by the patient of what he or she is capable of doing) are linked with pain-related psychological symptoms and behaviors.12 Poor copers employ few self-management strategies (such as using ice, heat, or relaxation strategies). A tendency to catastrophize often predicts poor outcome and disability, independent of other psychopathology, such as major depression. The duration of chronic pain and psychiatric co-morbidity are each independent predictors of pain intensity and disability. High levels of anger (which occur more often in men) can also explain a significant variance in pain severity.13

PAIN AND CO-MORBID PSYCHIATRIC CONDITIONS

Virtually all psychiatric conditions are treatable in patients with chronic pain, and the majority of patients who are provided with appropriate treatment improve significantly. Many physicians who treat pain patients often do not realize that this is the case. Of the disorders that most frequently afflict patients with chronic pain, major depression and anxiety disorders are the most common; moreover, they have the best response to medications. Whenever possible, medications that are effective for psychiatric illness and that have independent analgesic properties should be used. Independent analgesia refers to the efficacy of a pain medication (such as a TCA for neuropathic pain), which is independent of its effect on mood.14

Regardless of the type of psychopathology present, improvement in psychiatric symptoms results in a reduction of pain levels, in greater acceptance of the chronicity of pain, in improved function, and in an improved quality of life. Chronic pain may precipitate or worsen psychopathology and psychopathology may worsen pain. There is good evidence that psychiatric co-morbidity can be successfully treated, even if pain does not improve. It is important for the physician who treats pain to recognize psychiatric illness early in the course of chronic pain and to treat both conditions. In general, as with most psychiatric illnesses, a combination of pharmacological and psychotherapeutic treatments is more effective in treating depression and anxiety in pain patients than is pharmacological treatment alone.

Major Depression

The diagnosis and treatment of major depression in a patient with chronic pain is not significantly different from the approach to major depression in a patient with another medical illness. As in other patient groups, the combination of medications and cognitive-behavioral therapy (CBT) yields the best outcome.

Coping and Psychotherapy

Improving coping skills is a mainstay of treatment for any of the psychiatric conditions associated with chronic pain. In addition to improving psychological distress, use of active coping strategies improves pain and function (e.g., remaining active despite pain). Coping involves having adaptive defense mechanisms to negotiate maladaptive thoughts and feelings that arise in response to pain.

The psychodynamic aspects of coping involve conflicts over autonomy and care. Regression can be manifest as noncompliance, help-rejecting complaining, and behaviors akin to the metaphorical “cutting off your nose to spite your face.” Pain may make both patients and physicians appear hateful; psychiatrists are well served by clarifying how these problems get played out in the physician-patient relationship. To help the patient cope, the psychiatrist must be sensitive to the unconscious feelings of the patient; in addition, denial must be managed, and family counseling, relaxation, exercise, physical rehabilitation, and pharmacotherapy should be considered.

CBT in conjunction with antidepressant therapy is the most efficacious treatment for MDD, including MDD that worsens in the setting of chronic pain. Typically, CBT improves coping skills and self-efficacy, and diminishes catastrophization. When CBT is used the patient must be properly motivated, have sufficient insight, and have the ego strength to tolerate challenges to his or her beliefs. CBT in pain patients focuses on the thoughts and cognitive distortions that surround chronic pain (such as fear of re-injury, the belief that the only meaningful life is one without pain, and thoughts that the patient’s pain is not taken seriously by others).

Anxiety Disorders

Symptoms

Anxiety disorders encompass a broad spectrum of disorders (including generalized anxiety disorder [GAD], panic disorder, obsessive-compulsive disorder [OCD], and posttraumatic stress disorder [PTSD]). In addition, pain-related anxiety is the primary manner in which anxiety disorders are manifest in those with chronic pain.11 Anxiety is prevalent in chronic pain clinics, with 30% to 60% of the patients experiencing pathological anxiety.17 Among the anxiety disorders, GAD is the condition that most often afflicts pain patients. More than 50% of patients with anxiety disorders also have a current or past history of MDD or another psychiatric disorder. Alcohol and substance abuse commonly accompany chronic pain; consequently, recognition and treatment of co-morbid depression and substance abuse are critical to long-term treatment outcome.

In pain patients, situational (state) anxiety may be centered on the pain itself and its negative consequences (pain-anxiety). Patients may have conditioned fear, believing that activities will cause uncontrollable pain, causing avoidance of those activities. Pain may also activate thoughts that a person is seriously ill.11 Questions such as the following can be helpful: “Does the pain make you panic? If you think about your pain, do you feel your heart beating fast? Do you have an overwhelming feeling of dread or doom? Do you experience a sense of sudden anxiety that overwhelms you?”

Anxiety amplifies both the perception and complaints of pain through several bio-psycho-social mechanisms (e.g., sympathetic arousal that lowers the nociceptive threshold, increased firing of ectopically active pain neurons, excessive focusing on pain symptoms, and implementation of poor coping skills). Patients with pathological anxiety are often restless, fatigued, irritable, and concentrate poorly. They may also have muscle tension and sleep disturbances.

Somatoform Disorders

Classification

The somatoform disorders comprise a group of disorders in which complaints and anxiety about physical symptoms are the dominant features. These complaints exist in the absence of sufficient organic findings to explain the extent of a person’s pain. Most often there is a physical basis (including functional pathology, such as neuropathic pain) for at least a portion of the pain complaints, in which symptom-reporting is magnified by somatizing. Somatization is best thought of as a process. The spectrum of somatization includes amplification of symptoms, which entails “focusing upon the symptoms, racking with intense alarm and worry, extreme disability, and a reluctance to relinquish them.”20 Pain-related psychological symptoms amplify pain perception and disability. Hence, there is a tremendous overlap between the somatoform component of a chronic pain syndrome and other psychiatric co-morbidities. Four somatoform disorders may involve pain: somatization disorder, conversion disorder, hypochondriasis, and pain disorder (with or without a physical basis for pain). Somatoform disorders without any physical basis for pain are estimated to occur in 5% to 15% of patients with chronic pain who receive pain treatment.21

Symptom Presentation

Among somatizers, pains in the head or neck, epigastrium, and limbs predominate. Visceral pains from the esophagus, abdomen, and pelvis are associated with a high rate of psychiatric co-morbidity, particularly somatoform disorders, which can be challenging to diagnose.22 Missed ovarian cancers, neuropathic pain following inflammatory disorders, and referred pain are often overlooked because of the nonspecific presentations of visceral pain. Sufferers from somatoform disorders often have painful physical complaints and excessive anxiety about their physical illness. The most common co-morbid conditions among somatoform-disordered pain patients are MDD and anxiety disorders. Patients with somatization disorder consume health care resources at nine times the rate of the average person in the United States.

Pain Disorder

Pain disorder is defined in DSM-IV as a syndrome in which the focus of the clinical presentation is pain that causes significant impairment in occupational or social function, induces marked distress, or both. Organic pathology, if present, does not explain the extent of pain complaints or the degree of associated social and occupational impairment. Pain disorder has three subtypes: psychological (in which psychological factors play the primary role in the onset, severity, exacerbation, or maintenance of the pain); nonpsychiatric pain associated with a general medical condition; and combined type (pain associated with psychological factors and a general medical condition).

Pain disorder has been variously called psychogenic pain disorder, somatoform pain disorder, and pain behavior. When behavioral disability predominates, chronic pain syndrome is the behavioral description of this same syndrome. The meandering history of nomenclature is best understood as reflecting the mix of pain behaviors, as well as interpersonal and affective characteristics, that emphasize disability and entreat attention from others. Psychological antecedents of this syndrome may include a history of physical abuse, counterdependent personal relationships, a family history of alcoholism, and a personal developmental history of attachment problems. Co-morbid diagnoses (particularly depression, anxiety, and substance abuse) should be sought. Treatment must address the triad of self-defeating behavior, affective dysfunction, and psychodynamic conflicts, which causes poor coping, disability, and disrupted rehabilitation efforts.

GENERAL PRINCIPALS OF MULTIMODAL ANALGESIA

In the medication management of chronic pain, multimodal analgesia is the preferred method, since very commonly multiple receptor systems must be targeted to achieve optimal pain control. By logical extension, successful treatment of chronic pain typically involves the use of more than one medication, nerve blocks, physical therapy, and relaxation or biofeedback techniques (i.e., treatment is conducted by a multidisciplinary team or by an interdisciplinary pain medicine program). In general, treatment goals are reports of pain less than 5 out of 10 and an improvement in function. Typically, this corresponds to a 30% to 50% long-term improvement in chronic pain and an improved quality of life. Studies have shown that at a level of 4 out of 10 or below, most patents are able to perform most of their activities of daily living with satisfaction. A 30% improvement in pain has been shown to be the level that is clinically meaningful, a level at which most patients will feel significantly better. Many of the nerve blocks (such as epidural steroid injections) are effective for acute exacerbations of chronic pain. But their relatively short duration of efficacy (2 to 6 weeks on average) makes them inadequate for the long-term management of chronic pain, if they are used as the only treatment modality. Interventional procedures with longer-term efficacy include spinal cord stimulation, radiofrequency lesioning, and intrathecal pump implantation.

Major Medication Classes

Tricyclic Antidepressants

Tricyclic antidepressants (TCAs) are one of the primary medications used to treat neuropathic pain syndromes; TCAs have both independent analgesic properties and effects as adjuvant agents. A series of studies by Max and others14 have illustrated the analgesic properties of TCAs, which are independent of their effects on improving depression. TCAs have been shown to be effective for the pain associated with diabetic neuropathy, for chronic regional pain syndromes, for chronic headache, for post-stroke pain, and for radicular pain. While the early studies were done with amitriptyline and desipramine, subsequent studies have confirmed that other TCAs also have equivalent analgesic properties. Of note, the typical doses for the analgesic benefit of TCAs (25 to 75 mg) are lower than the doses generally used for antidepressant effect (150 to 300 mg). Nevertheless, there is a dose-response relationship for analgesia, and some patients benefit from a TCA used in the traditional antidepressant dose range, in conjunction with blood level monitoring. A TCA and an anticonvulsant are often combined for the treatment of chronic pain, and this combination facilitates treatment of mood disorders. Since pain patients are frequently on a variety of medications that may potentially increase TCA serum levels, the value of blood level monitoring, even at low doses, cannot be understated.

Opioids

Acute, severe, and unremitting pains in cancer patients, as well as non–cancer-related chronic pain, which have been refractory to other medication modalities typically requires treatment with opioids. At times, opioids are the most effective treatment for chronic, nonmalignant pain, such as the pain associated with postherpetic neuralgia, degenerative disorders, and vascular conditions. Nociceptive pain and absence of any co-morbid drug abuse have been associated with long-term opioid treatment efficacy. Morphine is often the initial opioid of choice for acute and chronic pain because it is well known to most physicians and has a good safety profile. Beyond these starting points, the basic principles of opioid treatment are outlined in Tables 78-3 and 78-4.

Table 78-3 Guidelines for Opioid Maintenance

Tramadol deserves special mention because it does have weak mu-opioid receptor activity, but it is not classified as a controlled substance in the United States. It also has SNRI properties. Its analgesic mechanism is unknown, but it is thought to enhance descending pain inhibition. Tramadol should not be prescribed concurrently with SSRIs because of a unique interaction that results in a dramatic reduction in seizure threshold. Caution should be taken when prescribing it with other medications (such as bupropion, TCAs, and neuroleptics) that also lower the seizure threshold.

Recent evidence suggests that patients should be screened for risk factors for opioid misuse or abuse (e.g., a current or past history of a substance use disorder [SUD], a family history of an SUD, a significant legal history, and a promi-nent affective disorder) before prescribing them, so that the physician can prescribe and monitor use of opiates appropriately. Once oral doses have been initiated and titrated to a satisfactory level, the analgesic effect needs to be sustained by minimizing fluctuations in blood levels and the variable effects of dosing schedules. Long-acting or controlled-release formulations are ideal for this homeostasis, because they are released more slowly than are short-acting opioids.

For the treatment of chronic pain, dosing with short-acting medications only on an as-needed basis should be avoided since this makes steady relief impossible. It also predisposes the patient to drug-respondent conditioning and to subsequent behavior problems. Typically, long-acting formulations are combined with short-acting agents for breakthrough pain. In those at risk for opioid misuse or with demonstrated aberrant drug behavior, only long-acting (such as a fentanyl patch) agents are preferred to avoid inappropriate self-medication. Other chapters in this text discuss strategies for the prescription of opiates to those with addiction. The most frequently reported side effects of opioid therapy are constipation, dry mouth, and sedation.

TREATMENT OF PAIN BEHAVIOR AND THE USE OF MULTIDISCIPLINARY PAIN CLINICS

Medicare guidelines offer a broad set of criteria to qualify for structured multidisciplinary pain management. The pain must last at least 6 months (and result in significant life disturbance and limited function), it must be attributable to a physical cause, and it must be unresponsive to the usual methods of treatment. Quality control guidelines developed by the Commission on Accreditation of Rehabilitation Facilities (CARF) have led to the certification of more than 100 multidisciplinary chronic pain management programs nationwide. Behavioral treatments are a key component of these programs and can be effective for the relief of pain and can help extinguish the behaviors associated with pain.

Inpatient or outpatient multidisciplinary pain treatment should be considered early in the course of chronic pain. This is particularly important when intensive observation is necessary (e.g., to rule out malingering); no single modality of outpatient treatment is likely to work; the patient has already obtained maximum benefit from outpatient treatments (such as NSAIDs, nerve blocks, antidepressants, and simple physical and behavioral rehabilitation); intensive daily interventions are required, usually with multiple concurrent types of therapy (such as nerve blocks, physical therapy, and behavior modification); and the patient exhibits abnormal pain behavior and agrees to the goals of improved coping, work rehabilitation, and psychiatric assessment.

REFERENCES

1 IASP Subcommittee on Taxonomy. Pain terms: a list with definitions and notes on usage. Pain. 1979;6(3):249-252.

2 Von Korff M, Crane P, Lane M, et al. Chronic spinal pain and physical-mental comorbidity in the United States: results from the National Comorbidity Survey Replication. Pain. 2005;113(3):331-339.

3 Walker EA, Keegan D, Gardner G, et al. Psychosocial factors in fibromyalgia compared with rheumatoid arthritis: II. Sexual, physical, and emotional abuse and neglect. Psychosom Med. 1997;59(6):572-577.

4 Fernandez E. Interactions between pain and affect. In Anxiety, depression, and anger in pain. Dallas: Advanced Psychological Resources; 2002.

5 Strain EC. Assessment and treatment of comorbid psychiatric disorders in opioid-dependent patients. Clin J Pain. 2002;18(4 suppl):S14-S27.

6 Sprenger T, Valet M, Boecker H, et al. Opioidergic activation in the medial pain system after heat pain. Pain. 2006;122:63-67.

7 Coghill RC, McHaffie JG, Yen YF. Neural correlates of interindividual differences in the subjective experience of pain. Proc Natl Acad Sci. 2003;100(14):8538-8542.

8 Gracely RH, Petzke F, Wolf JM, Clauw DJ. Functional magnetic resonance imaging evidence of augmented pain processing in fibromyalgia. Arthritis Rheum. 2002;46(5):1333-1343.

9 Zubieta JK, Ketter TA, Bueller JA, et al. Regulation of human affective responses by anterior cingulate and limbic mu-opioid neurotransmission. Arch Gen Psychiatry. 2003;60(11):1145-1153.

10 Nelson D, Novy D. Self-report differentiation of anxiety and depression in chronic pain. J Pers Assess. 1997;69(2):392-407.

11 McCracken L, Gross RT, Aikens J, Carnrike CLJr. The assessment of anxiety and fear in persons with chronic pain: a comparison of instruments. Behav Res Ther. 1996;34(11):927-933.

12 Keefe FJ, Rumble ME, Scipio CD, et al. Psychological aspects of persistent pain: current state of the science. J Pain. 2004;5(4):195-211.

13 Turk DC, Monarch ES. Biopsychosocial perspective on chronic pain. In: Turk DC, Gatchel R, editors. Psychological approaches to pain management. New York: Guilford Press, 2002.

14 Max MB, Lynch SA, Muir J. Effects of desipramine, amitriptyline and fluoxetine on pain in diabetic neuropathy. N Engl J Med. 1992;326:1250-1256.

15 McHugh P, Slavney P. The perspectives of psychiatry. Baltimore: Johns Hopkins University Press, 1998.

16 Gallagher RM, Verma S. Managing pain and co-morbid depression: a public health challenge. Semin Clin Neuropsych. 1999;4(3):203-220.

17 Koenig T, Clark MR. Advances in comprehensive pain management. Psychiatr Clin North Am. 1996;19(3):589-611.

18 Thase ME, Entsuah AR, Rudolph RL. Remission rates during treatment with venlafaxine or selective serotonin reuptake inhibitors. Br J Psychiatry. 2001;178(3):234-241.

19 Goldstein DJ, Lu Y, Detke MJ, et al. Duloxetine vs. placebo in patients with painful diabetic neuropathy. Pain. 2005;116:109-118.

20 Barsky AJ. Patients who amplify bodily sensations. Ann Intern Med. 1979;91(1):63-70.

21 Sigvardsson S, von Knorring A, Bohman M. An adoption study of somatoform disorders. Arch Gen Psychiatry. 1984;41(9):853-859.

22 McDonald J. What are the causes of chronic gynecological pain disorders? APS Bulletin. 1995;5(6):20-23.